Experimental AML combo trial halted early – what happened?

NCT ID NCT03055286

Terminated Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called CWP232291 combined with the standard chemotherapy cytarabine in 15 adults with acute myeloid leukemia (AML) that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for signs of effectiveness, but it was terminated early, so the full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CWP232291 (an experimental drug) combined with cytarabine (a standard chemotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for people with AML that has come back or not responded to other therapies.
What could go wrong: This was a very early, small trial that was terminated early, so we don't know if the drug works or is safe. The results may never be published.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Asan Medical Center

Seoul, Songpa-Gu, South Korea
Samsung medical center

Seoul, Gangnam-gu, South Korea
Seoul National University Hospital

Seoul, Jongno-gu, South Korea
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Washington

Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.